MET and hepatocellular carcinoma: Therefore, inhibition of SAAL1 expression could inhibit the growth and migration ability of HCC cells, impair the AKT/mTOR phosphorylation cascade driven by HGF/MET, and increase the sensitivity of HCC cells to sorafenib and foretinib [8].